Glioblastoma (GBM) is a highly aggressive type of brain cancer. Even with current standard of care, 50% of patients die within 15 months of diagnosis.
With a national grant of about S$10 million, researchers in Singapore are working with overseas collaborators to address these challenges and develop new diagnostic and treatment options so patients can receive effective targeted therapy.
The potential benefits of the project lie in being able to quickly and effectively identify the type of drug for patients.. Read more at straitstimes.com.